Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors' reply
2005; Elsevier BV; Volume: 6; Issue: 11 Linguagem: Inglês
10.1016/s1470-2045(05)70402-2
ISSN1474-5488
AutoresBryan Burmeister, B. Mark Smithers,
Tópico(s)Gastric Cancer Management and Outcomes
ResumoWe thank Pramesh and his co-authors for their comments about the Australasian Intergroup trial for resectable oesophageal cancer study IG 9401. 1 Burmeister BH Smithers BM Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005; 6: 659-668 Summary Full Text Full Text PDF PubMed Scopus (864) Google Scholar Our conclusions were conservative, and we agree that our sample-size calculations were based on outdated surgical data; 2 Muller JM Erasmi H Stelzner M et al. Surgical therapy of esophageal carcinoma. Br J Surg. 1990; 77: 845-857 Crossref PubMed Scopus (905) Google Scholar however, this data was the most useful available at the time the trial was designed. We attribute the good results in the control group to patient selection, improvements in clinical staging, and the involvement of experienced oesophageal surgeons. The survival outcomes were clinically (but not statistically) significant, especially with squamous-cell carcinoma. Neoadjuvant chemoradiotherapy in resectable oesophageal cancerWe commend Burmeister and colleagues1 on their randomised trial assessing the effect of neoadjuvant chemoradiotherapy on resectable oesophageal cancer published in the September issue of The Lancet Oncology. The investigators used a fairly non-toxic regimen (one cycle of 80 mg/m2 cisplatin with 800 mg/m2 fluorouracil and 35 Gy radiotherapy over 3 weeks), thereby ensuring good compliance with the planned treatment. However, we disagree with the investigator's conclusions that progression-free survival and overall survival does not improve with neoadjuvant chemoradiotherapy for oesophageal cancer. Full-Text PDF
Referência(s)